0000000000105811

AUTHOR

Antonio Ceriello

showing 17 related works from this author

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabe…

cardiovascular riskGlucose-lowering therapyEndocrinology Diabetes and MetabolismeducationSocieties Medical/standardsMEDLINE10265 Clinic for Endocrinology and DiabetologyHypoglycemic Agents/therapeutic use610 Medicine & healthType 2 diabetesHyperglycemia/drug therapyLifestyle modificationRisk FactorsDiabetes mellitusTier 2 networkADA Consensus StatementmedicineInternal MedicineInitial treatmentHyperglycaemiaHumansIn patientFor Debatealgorithmbusiness.industrynutritional and metabolic diseasesType 2 diabetesmedicine.diseaseCardiovascular riskUnited StatesMetforminEASD consensus statementglucose-lowering therapyAlgorithmEurope2712 Endocrinology Diabetes and Metabolism2724 Internal Medicine*AlgorithmsDiabetes Mellitus Type 2/complications/*drug therapytype 2 diabetesbusinessAlgorithmCardiovascular Diseases/prevention & controlhyperglycaemiamedicine.drug
researchProduct

The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO I…

2022

Coronavirus disease 2019 (COVID-19) is a highly heterogeneous disease regarding severity, vulnerability to infection due to comorbidities, and treatment approaches. The hypothalamic–pituitary–adrenal (HPA) axis has been identified as one of the most critical endocrine targets of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that might significantly impact outcomes after infection. Herein we review the rationale for glucocorticoid use in the setting of COVID-19 and emphasize the need to have a low index of suspicion for glucocorticoid-induced adrenal insufficiency, adjusting for the glucocorticoid formulation used, dose, treatment duration, and underlying health problems. We a…

Hypothalamo-Hypophyseal SystemHydrocortisoneSARS-CoV-2Organic ChemistryCOVID-19Pituitary-Adrenal SystemGeneral MedicineCatalysisComputer Science ApplicationsInorganic ChemistrySARS-CoV-2 adrenal insufficiency glucocorticoids hypercortisolism hypothalamic–pituitary–adrenal axisHumansPhysical and Theoretical ChemistryMolecular BiologyGlucocorticoidsSpectroscopyInternational journal of molecular sciences
researchProduct

Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

Pediatricsmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInternal MedicinemedicineType 2 diabetesErratummedicine.diseasebusinessDiabetologia
researchProduct

Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice

2021

Blood GlucoseGlycated Hemoglobinmedicine.medical_specialtybusiness.industryPharmacology toxicologyGeneral MedicineGlycated Hemoglobin A Humans Blood Glucose Diabetic AngiopathiesRheumatologyDilemmaClinical Practicechemistry.chemical_compoundchemistryInternal medicinemedicineHumansPharmacology (medical)Glycated hemoglobinbusinessIntensive care medicineDiabetic AngiopathiesGlycemic
researchProduct

COVID-19 and diabetes management: What should be considered?

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Clinical effectivenessbusiness.industryEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cardiovascular disease COVID-19 Diabetes DPP4 GLP-1RA Hydroxychloroquine Pioglitazone SGLT-2General Medicinemedicine.diseaseEndocrinologyDiabetes managementDiabetes mellitusInternal MedicinemedicineSodium-Glucose Cotransporter 2 InhibitorIntensive care medicinebusinessPioglitazonemedicine.drugDiabetes research and clinical practice
researchProduct

Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel

2021

Efforts in the fight against COVID-19 are achieving success in many parts of the world, although progress remains slow in other regions. We believe that a syndemic approach needs to be adopted to address this pandemic given the strong apparent interplay between COVID-19, its related complications, and the socio-structural environment. We have assembled an international, multidisciplinary group of researchers and clinical practitioners to promote a novel syndemic approach to COVID-19: the CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). This geographically diverse group aims to facilitate collaborative-networking and scientific exchanges between researchers and …

diabetescomplicationsRC666-701pandemicPerspectivesyndemicDiseases of the circulatory (Cardiovascular) systemCOVID-19Cardiovascular MedicineCardiology and Cardiovascular Medicinecardiovascular diseasesFrontiers in Cardiovascular Medicine
researchProduct

Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study

2020

AbstractEvidence regarding the relation between SARS-CoV-2 mortality and the underlying medical condition is scarce. We conducted an observational, retrospective study based on Romanian official data about location, age, gender and comorbidities for COVID-19 fatalities. Our findings indicate that males, hypertension, diabetes, obesity and chronic kidney disease were most frequent in the COVID-19 fatalities, that the burden of disease was low, and that the prognosis for 1-year survival probability was high in the sample. Evidence shows that age-dependent pairs of comorbidities could be a negative prognosis factor for the severity of disease for the SARS-CoV 2 infection.

MalePediatricsmedicine.medical_specialtyScienceDiseasesComorbidityDisease030204 cardiovascular system & hematologyCOVID-19 ; Medical research ; Diseases ; Risk factorsAged Aged 80 and over COVID-19 Comorbidity Diabetes Mellitus Ethnicity Female Humans Hypertension Male Middle Aged Obesity Pandemics Risk Factors Romania SARS-CoV-2Article03 medical and health sciencesMedical research0302 clinical medicineDiabetes mellitusDiabetes MellitusEthnicitymedicineHumansObesity030212 general & internal medicinePandemicsAgedAged 80 and overMultidisciplinaryRomaniaSARS-CoV-2business.industryQRCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseComorbidityObesityClinical trialRisk factorsHypertensionMedicineFemaleObservational studybusinessKidney disease
researchProduct

Post-COVID syndrome, inflammation, and diabetes

2022

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It i…

InflammationEndocrinologyCOVID-19 Long COVID New-onset diabetes Newly diagnosed diabetes Post-COVID syndrome SARS CoV-2 Syndemia Type 2 diabetesSARS-CoV-2Endocrinology Diabetes and MetabolismHyperglycemiaInternal MedicineDiabetes MellitusHumansCOVID-19RNA ViralPandemics
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct

Diabetes and renin-angiotensin-aldosterone system: Implications for covid-19 patients with diabetes treatment management

2020

In the context of the COVID-19 continuous spreading, this paper focuses on the increased risk of diabetic patients regarding the metabolic control and the uncertainties related to SARS-CoV-2 infection. Chronic hyperglycaemia negatively affects the immune system, which triggers an increase of morbidity and mortality for viral infections. A key aspect of COVID-19 resides in the involvement of renin-angiotensin-aldosterone (RAAS) system that causes a cascade of reactions mediated by vasoactive peptides with implications in vasoconstriction, vascular permeability, oxidative stress remodelling and tissue injuries. Activation of RAAS at pulmonary level, is responsible for the local damage. Many q…

010405 organic chemistrybusiness.industry030209 endocrinology & metabolismContext (language use)Vascular permeabilityACEi ARBs COVID-19 Diabetes Of renin-angiotensin-aldosterone system RAAS SARS-CoV-2medicine.diseasemedicine.disease_causeBioinformatics01 natural sciences0104 chemical sciences03 medical and health sciences0302 clinical medicineImmune systemMetabolic control analysisDiabetes mellitusRenin–angiotensin systemmedicineGeneral Pharmacology Toxicology and Pharmaceuticsmedicine.symptombusinessVasoconstrictionOxidative stress
researchProduct

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospectiv…

2016

Abstract Background Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. Methods We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subject…

Carotid Artery DiseasesMaleEndocrinology Diabetes and MetabolismPredictive Value of Test030204 cardiovascular system & hematologyCarotid intima-media thickne0302 clinical medicineRisk FactorsPrevalenceProspective StudiesCarotid intima-media thicknessProspective cohort studyOriginal Investigation2. Zero hungerIncretinMiddle AgedMetabolic syndromeMetformin3. Good healthMetforminTreatment OutcomeItalyCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyIncretin030209 endocrinology & metabolismIncretins03 medical and health sciencesPredictive Value of TestsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsCardiovascular risk Carotid intima-media thickness Liraglutide Metabolic syndromeAgedCarotid Artery DiseaseHypoglycemic AgentLiraglutidebusiness.industryRisk FactorBiomarkerLiraglutideCardiovascular riskmedicine.diseaseEchocardiography Doppler ColorProspective StudieDiabetes Mellitus Type 2Intima-media thicknessMetabolic syndromebusinessBody mass indexBiomarkersCardiovascular Diabetology
researchProduct

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health

2022

Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the…

Interleukin-6SARS-CoV-2Interleukin-8COVID-19COVID Cardiometabolic Diabetes Inflammation MolecularInterleukin-10Interferon-gammaAdipokinesDiabetes Mellitus Type 2Cardiovascular DiseasesCytokinesHumansInterleukin-2RNA ViralMolecular MedicineInterleukin-4ObesityPandemicsMolecular BiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Additional file 1: of Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Table S1. Clinical characteristics of patients at baseline and at 4-year grouped by of basal GFR. (DOCX 20 kb)

urologic and male genital diseases
researchProduct

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Background Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage ≥3 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage ≥3 CKD in a large cohort of patients affected by T1DM. Methods A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici D…

AdultMaleNephrologymedicine.medical_specialtyendocrine system diseasesRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologylcsh:RC870-923Kidneyurologic and male genital diseasesGFR03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusmedicineHumansAlbuminuriaDiabetic kidney diseaseKidneyType 1 diabetesurogenital systembusiness.industryIncidence (epidemiology)Middle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseasefemale genital diseases and pregnancy complicationsAlbuminuria Diabetic kidney disease GFR NephrologyDiabetes Mellitus Type 1medicine.anatomical_structureItalyNephrologyDisease ProgressionAlbuminuriaFemalemedicine.symptombusinessResearch ArticleFollow-Up StudiesGlomerular Filtration RateKidney disease
researchProduct

Additional file 2: of Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Table S2. Baseline clinical characteristics of patients grouped by eGFR and albuminuria. (DOCX 19 kb)

urologic and male genital diseasesfemale genital diseases and pregnancy complications
researchProduct

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact

2022

: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has been shown to disrupt many organ systems in the human body. Though several medical disorders have been affected by this infection, a few illnesses in addition may also play a role in determining the outcome of COVID-19. Obesity is one such disease which is not only affected by the occurrence of COVID-19 but can also result in a worse clinical outcome of COVID-19 infection. This manuscript summarizes the most recent evidence supporting the bidirectional impact of COVID-19 and obesity. It highlights how the presence of obesity can be detrimental to the outcome of COVID-19 in a given …

Syndemic.SARS-CoV-2Endocrinology Diabetes and MetabolismInternal MedicineBidirectional impactCOVID-19Obesity
researchProduct

Data on the age, sex, comorbidities, and location of the COVID-19 fatalities in Romania

2021

This dataset consists of 2 .xlsx spreadsheet and 1 .Rmd R markdown file. These data underlie the related manuscript: "Death by SARS-CoV 2 - a Romanian COVID-19 multi-centre comorbidity study".The related study investigated the relationship between SARS-CoV-2 mortality and underlying medical conditions via an observational, retrospective study based on Romanian official data about location, age, sex and comorbidities for COVID-19 fatalities.The data files are as follows:- Pantea Stoian et al Death by SARS-CoV 2 -PneumoniaCOVID19_data.xlsx: This spreadsheet contains all the data on COVID-19 comorbidities gathered in the related study. The data are de-identified to protect patient privacy.- De…

researchProduct